Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Derivative exercise or conversion — not an open-market buy.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
Sep 30, 2026
Reporting period
Not applicable
Filed with the SEC
Oct 2, 2026
DirectorIndirect holdingOption exercise
Context
Classification
option exercise
Code M — exercise or conversion of a derivative security
Planned / mechanical clue
Footnote references vesting of compensation awards
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0001193125-26-412431
Filed / recorded
Oct 2, 2026, 8:30 PM UTC
Added to OQRO
Oct 7, 2026, 2:00 PM UTC
Parser
form4-xml-v2
Data quality
Verified: identifiers matched exactly
Issuer
NewAmsterdam Pharma Co N.V.
Issuer CIK
1936258
Ticker
NAMS
Reporting person
Johannes Jacob Pieter Kastelein
Relationship
Director, Officer
Officer title
Chief Scientific Officer
Security
Option (right to buy)
Table
Derivative (Table II)
Transaction date
Sep 30, 2026
Transaction code
M
Shares / units
50,246
Price per share
$0.00
Acquired / disposed
Disposed (D)
Shares owned after
344,983
Ownership form
Indirect — See footnote
Amendment
No
Footnotes from the filing
The exercise price of the option is EUR 1.16392.
The option was granted on November 22, 2022 to replace an option originally granted on July 6, 2021 which was cancelled in connection with the consummation of NewAmsterdam Pharma Company N.V.'s business combination with Frazier Lifesciences Acquisition Corporation. 292,214 of the shares underlying the option immediately vested on the grant date. 25% of the remaining shares underlying the option vested on January 1, 2021, the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date.
The option was granted to and is held by Futurum through NAP PoolCo B.V. ("PoolCo") for the benefit of the Reporting Person. The Reporting Person exercises sole voting and investment control over the securities held by Futurum through PoolCo. PoolCo has no voting or investment control or pecuniary interest in the securities held on behalf of Futurum. Upon exercise of the option, the Ordinary Shares were issued to Futurum directly, pursuant to a written agreement among Futurum, PoolCo and the Issuer.
4 tracked managers disclosed the same change for Q2 2026. From a 13F filed Aug 14, 2026 covering holdings at Jun 30, 2026 — a quarter-end snapshot, not a live trade.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.